CNBG said its experimental coronavirus vaccine has raised antibodies in clinical trials.
Beijing / Singapore:
China National Biotec Group (CNBG) said on Tuesday that its experimental coronavirus vaccine has raised antibodies in clinical trials and that the company plans to carry out advanced human trials in foreign countries.
No vaccine has been proven to be effective in protecting people from the virus that has killed more than 400,000 people, while several candidates are at various stages of development around the world.
The vaccine, developed by a Wuhan-based research institute affiliated with CNBG’s parent company Sinopharm, has been shown to induce high-level antibodies in all people inoculated without a serious adverse reaction, according to preliminary data from a clinical trial. launched in April involving 1,120 healthy participants aged 18 to 59.
CNBG said it is proactively looking for large-scale and advanced stage 3 testing opportunities abroad.
“[We] have obtained an intention to cooperate with companies and institutes in many countries, “the company said in a statement.
State media reported that the candidate vaccine, along with another experimental shot developed by the Sinopharm unit, had been offered to Chinese employees of state-owned enterprises traveling abroad as the developers searched for more data on their effectiveness.
China has five candidate vaccines for COVID-19 in human trials, the highest number in any country.
Chinese vaccine maker Sinovac Biotech (Sinovac) released positive preliminary clinical trial results over the weekend for its potential vaccine candidate, which is expected to be tested in a phase 3 trial in Brazil.
